Highlights Xencor, Inc.

Equities

XNCR

US98401F1057

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
24.11 ^USD	+2.03%		+20.67%	+13.57%

Apr. 16	BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	MT
Apr. 09	Xencor Names Bart Cornelissen as Chief Financial Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M	Feb. 27	MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Xencor, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Genentech, Inc	Nov. 15	CI
Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $59.2M, vs. Street Est of $30M	Nov. 07	MT
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Xencor, Inc. and OCM Life Sciences Portfolio LP, Entere into A Royalty Purchase Agreement	Nov. 07	CI
Xencor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (XNCR) XENCOR Reports Q2 Revenue $45.5M, vs. Street Est of $26.3M	23-08-03	MT
Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress	23-05-30	CI
Xencor Reports Q1 Loss, Lower Revenue	23-05-08	MT
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Earnings Flash (XNCR) XENCOR Posts Q1 Revenue $19M, vs. Street Est of $26.9M	23-05-08	MT
Xencor's Swings to Q4 Loss, Revenue Drops	23-02-23	MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
Earnings Flash (XNCR) XENCOR Reports Q4 Revenue $21.6M, vs. Street Est of $19.2M	23-02-23	MT
Atreca, Inc. and Xencor, Inc. to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target	23-02-06	CI
Caris Life Sciences, Inc and Xencor, Inc. Expands Target Discovery Collaboration for Novel XmAb(R) Antibody Drug Candidates	23-01-05	CI
Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting	22-12-12	CI
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xencor, Inc.

Equities

XNCR

US98401F1057

Highlights

Filters